uniQure N.V.

QURE Healthcare Biotechnology

uniQure N.V.’s revenue for fiscal 2025 (year ended December 2025) was $16.1 million, down 40.6% from fiscal 2024. In the quarter to June 2026, revenue grew 11.0%, EPS fell 76.8%, free cash flow grew 27.7% and total debt fell 3.27%, each against the same quarter a year earlier.

21.72 0.80 −3.55%
Market cap
$1.6B
P/E
0.0×
Fwd P/E
−7.7×
Dividend yield
—
F-score
5/9
Altman Z
−0.80
Beneish M
−2.95
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Cash and Short Term Investments
132.50 159.37 234.90 377.79 244.93 556.26 352.84 617.89 367.52 622.54
Receivables
9.18 1.59 0.23 0.95 6.62 58.77 102.38 4.19 5.88 5.86
Inventory
0.48 — — — — — 6.92 12.02 — —
Other current assets
1.27 0.69 0.33 0.75 3.02 2.68 2.81 2.66 7.61 7.08
Total current assets
143.95 162.78 236.58 384.21 258.91 628.24 476.77 651.85 390.29 655.99
Property, Plant, Equpment (Net)
35.70 34.28 29.18 28.77 32.33 43.51 50.53 46.55 20.42 13.80
Long-Term Investments
1.83 2.48 2.44 2.93 2.75 — 39.98 2.18 27.46 30.24
Goodwill and Intangible Assets (Total)
8.79 10.10 5.71 5.92 3.90 90.32 84.36 86.86 93.46 98.15
Long Term Assets (Tax, Deferred)
— — — — 16.42 15.65 14.53 12.28 9.86 8.65
Long-term assets (Other)
1.83 2.48 2.44 2.93 2.75 5.90 6.06 3.18 1.40 5.56
Total non-current assets
46.32 46.86 37.33 64.42 81.48 180.94 228.19 179.84 166.25 168.92
Total Assets
190.27 209.64 273.91 448.63 340.40 809.18 704.96 831.69 556.54 824.91
Accounts Payable
5.52 2.91 3.79 5.68 3.77 2.50 10.98 6.59 7.23 5.17
Accrued Expenses
9.77 8.84 8.23 12.46 18.04 28.49 30.57 30.53 29.23 41.29
Current Part of Debt
0.61 1.05 8.23 — — — — — — —
Current Revenue (Deferred)
6.14 4.61 7.63 7.63 — — — — — —
Other current liabilities
0.68 1.82 0.31 20.08 18.04 28.49 25.98 28.21 — 12.60
Total current liabilities
22.72 19.23 19.97 31.63 27.33 36.76 75.92 73.68 40.05 62.92
Long Term Debt (Total)
19.63 19.74 35.47 36.06 35.62 100.96 102.79 101.75 51.32 49.70
Non-current Revenue (Deferred)
75.61 67.41 28.86 23.14 — — — — — —
Long Term Tax Liability (Deferred)
1.09 0.21 0.23 — (16.42) 12.91 8.26 7.54 7.04 7.97
Non-current Liabilities (Other)
8.67 13.91 10.00 3.61 3.14 33.78 10.27 412.74 453.73 495.59
Total non-current liabilities
103.91 101.06 74.33 93.94 69.16 176.64 153.04 550.34 523.24 563.09
Total liabilities
126.63 120.29 94.30 125.57 96.49 213.40 228.96 624.02 563.29 626.01
Additional Paid In Capital
464.65 566.53 720.07 986.80 1,016.02 1,076.97 1,113.39 1,148.75 1,173.07 1,582.37
Common Stock (Net)
1.59 1.95 2.30 2.65 2.71 2.80 2.84 2.88 2.95 3.69
Retained Earnings
(396.06) (475.32) (535.51) (659.71) (784.73) (455.14) (581.93) (890.41) (1,129.96) (1,328.94)
Common Equity (Total)
63.63 89.36 179.61 323.06 243.91 595.78 476.01 207.67 (6.75) 198.90
Shareholders Equity (Total)
63.63 89.36 179.61 323.06 243.91 595.78 476.01 207.67 (6.75) 198.90
Shareholders Equity and Liabilities (Total)
190.27 209.64 273.91 448.63 340.40 809.18 704.96 831.69 556.54 824.91
Shares (Common)
25.26 31.34 37.35 43.71 44.78 46.30 46.97 47.83 48.99 62.34
Shareholders Equity (Tangible)
54.84 79.26 173.90 317.14 240.00 505.46 391.65 120.81 (100.21) 100.76
Net Debt
(112.26) (138.58) (191.19) (341.73) (209.31) (455.29) (250.05) (516.14) (316.20) (572.84)
Total Debt
20.24 20.79 43.70 36.06 35.62 100.96 102.79 101.75 51.32 49.70

Fold the line items

In millions of $ except per-share values · columns are period end dates